BELLUS Health Inc.

BLU

$14.75

Updated: 24/09/2026, 12:09:11

Market Cap

$1.87B

Sector

Healthcare

Industry

Biotechnology

Country

No historical data available

Company Profile

BELLUS Health Inc. is a clinical-stage biopharmaceutical company headquartered in Laval, Canada, and founded in 1993. The firm focuses on developing therapeutic solutions for refractory chronic cough (RCC) and other related cough hypersensitivity conditions. Its leading product candidate, BLU-5937, an antagonist designed to block the P2X3 receptor, is currently progressing through Phase II clinical trials for the treatment of both RCC and chronic pruritus.

USD

NASDAQ

CEO: Roberto Francesco Bellini

Employees: 74

https://gsk.com

Asset Summaries

Latest generated summaries for BLU

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for BLU.

Share price: $14.75
Market cap: $1.87B
Exchange: NASDAQ
Currency: USD
CEO: Roberto Francesco Bellini
Employees: 74
IPO date: 27/10/2000
Beta: -0.27898
Last dividend: $0.00
Day range: $14.74 – $14.75
52-week range: $6.38 – $14.76
1-day performance: 0.03%
1-year performance: 131.11%
Current drawdown (1Y): -0.10%
CIK: 0001259942
CUSIP: 07987C204
ISIN: CA07987C2040
Created: 07/12/2025, 03:02:13
Last update: 24/09/2026, 12:09:11

Track BELLUS Health Inc. with an AI analyst

See which prediction-market events move BLU, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to BLU from your Railway `news_articles` table.

No news found for this symbol.